
Opinion|Videos|June 2, 2025
Early Detection of ccRCC
Panelists discuss how deep learning applied to imaging data sets may advance kidney cancer assessment, though they believe the next major leap will require true molecular imaging that reveals what tumors are expressing.
Advertisement
Episodes in this series

Future Directions for Imaging in Kidney Cancer
Main Discussion Topics:
- Potential for deep learning and artificial intelligence (AI) to extract additional information from imaging data sets
- Recognition that computational approaches have limitations
- The future likely requires molecular imaging that assesses tumor expression patterns.
Key Points for Physicians:
- AI and deep learning may identify imaging features not apparent to human readers.
- Computational approaches alone may have limitations.
- Molecular imaging represents the next frontier in renal mass characterization.
Notable Insights:
Although AI approaches show promise, the experts believe the most significant advances will come from molecular imaging techniques that directly assess tumor biology.
Clinical Significance:
Combination of computational approaches and molecular imaging will likely provide the next major advance in renal mass characterization.
Advertisement
Related to this article

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.

Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Advertisement
Advertisement

